3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
28
Rectal Neoplasms
6
Colonic Neoplasms
6
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Neutropenia
2
Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumors
2
mCRC
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Sarcoma, Ewing
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Interventions
Nivolumab
3
Oxaliplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
sintilimab
1
relatlimab
1
regorafenib
1
dabrafenib
1
copanlisib
1
atezolizumab
1
Tiragolumab
1
Leucovorin
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
Fluorouracil
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
trifluridine tipiracil drug combination
×
1 year
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled